Galectin Therapeutics CMO Jamil Khurram disposes of 16,250 common shares for $83,284.5

• Galectin Therapeutics Chief Medical Officer Jamil Khurram exercised options for 16,250 common shares at USD 3.04 on July 14.
• He sold 16,250 common shares the same day at a weighted average price of USD 5.13, ending with zero shares directly owned.
• He reported 48,750 stock options held following the transaction.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Galectin Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001133416-26-000063), on July 16, 2026, and is solely responsible for the information contained therein.